Search

Your search keyword '"Crosby, Margaret R."' showing total 13 results

Search Constraints

Start Over You searched for: Author "Crosby, Margaret R." Remove constraint Author: "Crosby, Margaret R." Database Unpaywall Remove constraint Database: Unpaywall
13 results on '"Crosby, Margaret R."'

Search Results

1. Supplementary Data from Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma

2. Supplementary Data from Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma

3. Supplementary Data from Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma

4. Data from Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma

5. Supplementary Data from Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma

6. Table S2 from Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma

7. Table S2 from Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma

8. Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma

9. PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma

10. A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy

11. SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis

12. SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis

13. A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy

Catalog

Books, media, physical & digital resources